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Abstract
Background: Patients undergoing elective total hip replacement (THR) surgery are at an increased risk for venous
thromboembolic events (VTEs). Dalteparin and enoxaparin are recommended as thromboprophylaxis for at least
10 days in these patients. Even though both agents have proven clinical effectiveness through placebo controlled
studies, there have been no head to head trials to assess comparative effectiveness. Indirect statistical techniques
were used to compare safety and efficacy between dalteparin and enoxaparin following THR surgery.
Methods: A literature search was conducted from January 1980 to November 2009 for randomized trials
evaluating dalteparin or enoxaparin prophylaxis in THR patients. In trials where a common control was used (e.g.
placebo), indirect statistical comparisons between dalteparin and enoxaparin were performed using meta
regression analysis with active drug as the primary independent variable.
Results: A total of nine placebo controlled enoxaparin (n = 5) and dalteparin (n = 4) trials met the inclusion
criteria. THR patients treated with enoxaparin or dalteparin had a 50% VTE risk reduction compared to the placebo
control (RR = 0.50, p < 0.001). This benefit was achieved without a significant increase in the risk for major bleeds
(RR = 1.19, p = 0.76), heparin induced thrombocytopenia (HIT) (RR = 1.13, p = 0.83) or death (RR = 0.72, p = 0.59).
The indirect comparison was not able to find significant differences between enoxaparin and dalteparin in terms of
VTEs (p = 0.36), major bleeds (p = 0.45), HIT (p = 0.48) and death (p = 0.86).
Conclusions: The findings suggested comparable safety and efficacy between dalteparin and enoxaparin in TKR
patients. Therefore, treatment decisions should be based on other considerations, such as patient or physician
preference, ease of administration and cost.
Introduction
Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are manifestations of venous thromboembolic
events (VTE). The primary cause of a PE is a DVT. Fol-
lowing invasive procedures such as orthopedic surgery,
patients are at risk for developing a DVT and subse-
quent PE.
1 This is a major clinical concern because PE
can be fatal in 70% of cases, usually within the first few
hours [1]. DVT and PE can also be common events in
hospitalized patients. In one claims based study, it was
determined that 0.64% (i.e. 32,193 cases) of all patients
discharged from evaluated U.S. hospitals between 1998
to 2004 had DVT or PE as the primary discharge diag-
nosis, and 26,159 (0.52%) had DVT or PE as a secondary
discharge diagnosis [2]. In the U.S., the high prevalence
of VTE translates to a cost impact of approximately
$2.9 billion annually [3].
To prevent VTE and avoid the associated health care
costs, thromboprophylaxis following major orthopedic
surgeries such as total hip replacement (THR) is standard
practice. According to the American College of Chest
Physicians (ACCP) guidelines, either a low molecular
weight heparin (LMWH), or warfarin are recommended
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undergoing THR [4]. Extended prophylaxis for up to
35 days is also recommended in patients undergoing
major orthopedic surgery, particularly for those at high-
risk of DVTs [4]. The LMWH have some practical advan-
tages over other agents. Anticoagulation therapy with
warfarin or unfractionated heparin (UH) can be proble-
matic in some patients because of the potential for drug-
drug interactions and unpredictable anticoagulation
levels secondary to liver dysfunction and poor patient
nutrition [4,5]. In addition, there is a need to closely
monitor patients receiving these alternative drugs.
Two of the most commonly used agents in the U.S.
include enoxaparin and dalteparin. Despite being avail-
able for clinical use since the early 1990s, there are no
large head to head randomized phase III studies between
dalteparin and enoxaparin in patients undergoing major
orthopedic surgeries such as THR. Physicians have been
relying on “gut feeling” as opposed to empirical evidence
that the products have comparable safety and efficacy. In
the absence of a randomized trial, statistical methods can
be used to indirectly evaluate two drugs. The advantages
of using indirect statistical techniques to conduct com-
parative effectiveness evaluations are that they utilize the
best available evidence to provide answers to questions
that have not been addressed through a randomized trial.
There are several example in the literature where indirect
statistical analysis has been used to conduct comparative
effectiveness research in diverse therapeutic areas such as
kidney cancer and pulmonary arterial hypertension [6,7].
In this study, two unique statistical techniques were used
to perform an indirect clinical comparison on the safety
and efficacy between dalteparin and enoxaparin in
patient undergoing THR surgery.
Methods
Literature Review and Meta Analysis of Randomized Trials
A computer literature search of PubMed, Embase, the
Cochrane Database and Google Scholar was conducted
from January 1980 to November 2009 for randomized
trials evaluating dalteparin and enoxaparin for the pre-
vention of VTEs in patients undergoing THR. Search
terms consisted of {dalteparin or enoxaparin}, AND
{prophylaxis} AND {THR}, OR {orthopedic surgery},
AND {randomized clinical trial}”.
The inclusion criteria for trial acceptance consisted of
the following:
￿ The trial must have utilized a parallel group
design. Cross over trials were excluded given the
inherent contamination from latent treatment effects
in their overall design.
￿ The trial population must have consisted of
patients undergoing THR.
￿ Must have enrolled patients greater than 18 years
of age.
￿ The control arm in accepted trials must have been
placebo, UH or warfarin.
￿ Accepted trials must have evaluated the clinically
appropriate doses of dalteparin or enoxaparin in at
least one of the trial arms
￿ Trials must have been a randomized comparison
with at least 25 patients enrolled into each arm.
Once the trials meeting the inclusion criteria were
identified, the following data were extracted: baseline
patient information, indication, sample size in each
group, drug and dosage, duration of therapy, study dura-
tion, definition of primary and secondary endpoints, pri-
mary and secondary results. Other data extracted from
the accepted THR trials consisted of number of proxi-
mal, distal, symptomatic DVTs and PE in each group.
Safety data consisted of bleeding events (minor and
major), heparin induced thrombocytopenia (HIT), num-
ber of withdrawals caused by adverse drug reaction and
all cause mortality in each of the study groups.
All of the study outcomes were presented as binary end-
points (e.g. VTE rates, major bleeding events) and were
combined using a fixed or random effects model in cases
of significant heterogeneity [8]. Random-effects meta-ana-
lysis assumes that the effect of the intervention varies
across studies. When significant between-study variation is
present, the 95%CI for the summary measure tends to be
larger with a random-effects model. Treatment effects
from individual trials were also presented as Forest Plots.
Statistical heterogeneity between studies was assessed
by both the Q-statistic and the I
2 test statistic [9]. Briefly,
the I
2 statistic measures the proportion of variance across
studies due to heterogeneity. It is considered to be
a superior measure of study heterogeneity than the
Q-statistic because the latter is often underpowered
when evaluating homogeneity in meta analyses. The
p-values associated with the Q-statistic (chi-square with
k-1 degrees of freedom, where K is the number of
studies) were also reported. In situations where the
Q-statistic was statistically significant or the I
2 statistic
was greater than 25%, a random effects meta analysis
model was used as described earlier. Publication bias was
assessed through an evaluation of funnel plots and by the
method proposed by Egger, which provides a significant
p-value when publication bias may be present [10,11].
Indirect Statistical Comparisons between Drugs
For each patient population, the indirect statistical
assessment between dalteparin and enoxaparin was per-
formed using two approaches. The first indirect method
was a meta regression analysis on the primary clinical
outcomes and on adverse event rates reported in the
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method for conducting an indirect comparison in cases
where trials evaluating the drugs of interest used a com-
mon comparator. Therefore, indirect comparisons
between dalteparin and enoxaparin were performed with
those trials that had the same control group. Separate
analyses were performed using placebo and UH as the
common control. Active drug (dalteparin and enoxa-
parin) was the independent variable in the regression
model [7,12]. Other independent variables considered in
the models included duration of therapy, treatment
schedule (pre vs. post surgery initiation), geographic
region where the study was conducted (i.e. North Amer-
ica vs. Europe vs. global) and year of publication. All of
these analyses were performed using Stata, V 9.0 (Stata
Corp., College Station, Texas, USA).
Indirect treatment comparisons were also performed
using the method of Bucher and colleagues, which partly
maintains the benefits of randomization on the effect
size [13,14]. Briefly, this is a simple method for an
adjusted analysis, in which the indirect comparison of A
and B is adjusted according to the results of the direct
comparisons with a common intervention - C. Let
lnORAC denote log odds ratio of A1 versus C1 in trial 1,
and lnORBC denote log odds ratio of B2 versus C2 in
trial 2. The log odds ratio of the adjusted indirect com-
parison of A and B (lnOR’AB) can then be estimated by:
￿ lnOR’AB = lnORAC - lnORBC
￿ The standard error would be: SE(lnOR’AB)=√ [SE
(lnORAC)
2 + SE(lnORBC)
2].
Although an odds ratio is used in the above equations,
this adjusted method may also be used when the relative
efficacy is measured as a relative risk, risk difference or
mean difference. Empirical evidence indicates that results
of adjusted indirect comparison are usually, but not
always, similar to those of direct head-to-head trials [15].
It is important to make a distinction between the two
methods for indirectly comparing dalteparin to enoxa-
parin. In the meta regression approach, the evaluation is
between a LWMH (dalteparin and enoxaparin) vs. a
common control (i.e. placebo or UH) and the effect
measure is expressed as a relative risk difference
between drugs. In contrast, the method of Bucher et al.,
uses a common comparator (e.g. placebo) to statistically
link the two treatments. As a result, the generated out-
come is an effect measure (RR in this case) comparing
enoxaparin to dalteparin with an associated p-value for
statistical significance [13,14].
Results
A total of 150 citations were identified and reviewed.
A total of 17 randomized trials meeting the inclusion
criteria were appropriate for the statistical pooling exer-
cise. Reasons for study rejection included duplicate pub-
lications, no active comparator, comparator other than
placebo, UH or warfarin, less than 25 patients enrolled
into each trial arm, dose finding study and patient popu-
lation were non-THR. In 16 of the trials, the two com-
mon comparators to the LMWHs were either placebo
or UH. There were no studies where warfarin was a
common control for both drugs (Table 1).
There were a total of 11 and 6 published randomized
trials evaluating enoxaparin and dalteparin in this
patient population (Table 1). Of the 11 enoxaparin trials,
five were against placebo (one evaluating three enoxa-
parin arms), and six had UH in the control arm. With
dalteparin, there were four placebo controlled trials, one
was against warfarin and the remaining one was relative
to UH. To apply the statistical techniques for the indir-
ect comparison, a common control group is required.
Therefore, separate analyses were conducted for the pla-
cebo and the UH controlled trials. This provided a total
of nine placebo trials and seven against UH for the two
drugs. A comparison using warfarin as a common con-
trol could not be conducted because there were no such
trials for enoxaparin.
Indirect Comparison using Placebo as the Common
Control
The nine placebo controlled trials provided a total of 11
treatment arms, six and five for enoxaparin and dalte-
p a r i nr e s p e c t i v e l y( T a b l e1 ) .T h eV T Ei n c i d e n c ed a t a
were pooled for all trials regardless of the LMWH used.
The findings revealed that THR patients treated with a
LMWH had a 50% reduction in the risk of a post surgi-
cal VTE (RR = 0.50, p < 0.001) - (Figure 1). Similarly,
there was no indication that either LMWH was asso-
ciated with neither an increase in the risk of major
bleeds relative to placebo (Figure 2) nor any of the
other relevant adverse events (Table 2).
A meta regression model with “active drug” (enoxa-
parin vs. dalteparin) was then developed to compare
VTE risk between drugs. The results were unable to
find statistically significant difference between enoxa-
parin and dalteparin in the risk of VTEs in patients
undergoing THR surgery (RR difference = 12%, p =
0.36). Similarly, there were no significant risk differences
between LMWH dosing schedules (pre vs. post surgery
initiation), treatment duration (< 15 days vs. extended
therapy), trial location and year of publication (Table 2).
T h es e c o n dp h a s eo ft h em e t ar e g r e s s i o na n a l y s i sw a s
an assessment of safety in terms of major bleeds, HIT
and death. Comparing the two LMWH to placebo, there
were no significant differences in any of these adverse
events suggesting that both enoxaparin and dalteparin
are safe to use in patients undergoing THR (Table 2).
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Study Sample
Size (n)
Study Drug vs. Control Results (n) Major Bleeds (n) HIT (n) Deaths
(n)
Dechavanne,1989
[17]
D1 = 42
D2 = 41
H=4 1
D - 2500 IU SC 2 h pre-op, then q 12 h post-op × 10-13 days DVT (all)
D1 - 2
D2 - 3
H-4
D1 - 0
D2 - 0
H-0
D - 2500 IU SC 2 h pre-op, then q 12 h post-op × 48 h, then 5000 IU q AM × 10-13 days DVT (proximal)
D1 - 1
D2 - 1
H-3
H - 5000 IU SC 2 h pre-op, then bid × 2 days post-op, then H dosage was adjusted
according to aPTT × 10-13 days
Tørholm, 1991
[16]
D=6 0
P=6 0
D - 2500 IU SC 2 h pre-op and 12 h post-op, then 5000 IU qAM × 6 days DVT
D-9
P-1 9
D-1
P-0
P - 2 h pre-op and 12 h post-op, then qAM × 6 days PE
D-0
P-1
Dahl, 1997 [19] D = 134
P = 131
D - 5000 IU SC evening before op and qPM × 7 days, then 5000 IU SC qPM × 28 days (±2
days)
DVT within first 7 days
D-4
P-3
D-0
P-0
D-0
P-0
P - 5000 IU SC evening before op and qPM × 7 days, then placebo × 28 days (±2 days) DVT within 35 days
D-2 2
P-2 3
PE within 35 days
D-0
P-1
Lassen, 1998 [20] D = 140
P = 141
D - 5000 IU SC qd, starting 12 h pre-op and × 7 days post-op; then 5000 IU qd × 28 days DVT (all)
D-5
P-1 2
D-0
P-1
D-0
P-1
P - 5000 IU SC qd, starting 12 h pre-op and × 7 days post-op; then placebo × 28 days DVT (proximal)
D-1
P-5
PE
D-0
P-0
Hull, 2000a [21] D1 = 504
D2 = 494
W = 500
D1 (pre-op) - 2500 IU SC within 2 h before surgery, then 2500 IUSC 4 or more h after
surgery, then 5000 IU SC qAM × 6 days (±2)
DVT (all)
D1 - 36
D2 - 44
W-8 1
First 8 days
D1 - 44
D2 - 32
W-2 2
D1 - 6
D2 - 4
W-1 0
D1 - 2
D2 - 0
W-2
D2 (post-op) - Placebo within 2 h before surgery, then 2500 IU SC 4 h or more after surgery,
then 5000 IU SC qAM × 6 days (±2)
DVT (proximal)
D1 - 3
D2 - 3
W-1 1
W - 10 mg PO evening after surgery (5 mg if ≥ 70 years old), then qd dosing by nomogram
× 6 days (±2)
PE
D1 - 0
D2 - 0
W-0
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Hull, 2000b [22] D1 = 199
D2 = 190
W = 180
D (pre-op) - 2500 IU SC within 2 h before surgery, then 2500 IU SC 4 or more h after
surgery, then 5000 IU qAM in-hospital, then 5000 IU qd up to 35 days (±2)
DVT (all) out of hospital
within first 35 days
D1 - 8
D2 - 6
P-1 4
Major bleeds out of
hospital within first 35
days
D1 - 0
D2 - 0
P-0
D1 - 0
D2 - 0
P-0
D1 - 0
D2 - 0
P-1
D (post-op) - 2500 IU SC 4 or more h after surgery, then 5000 IU qAM in-hospital; then 5000
IU qd up to 35 days (±2)
DVT (proximal) out of
hospital within first 35
days
D1 - 2
D2 - 1
P-7
W - 10 mg PO evening after surgery (5 mg if ≥ 70 years old or < 57 kg), then qd dosing by
nomogram in-hospital, then placebo up to 35 days (±2)
PE out of hospital
within first 35 days
D1 - 0
D2 - 0
P-0
Turpie, 1986 [23] E = 50
P=5 0
E - 30 mg SC bid, started 12-24 h post-op, then qd × 14 days or until discharge DVT (all)
E-6
P-2 1
E-1
P-2
E-0
P-1
P - 30 mg placebo SC bid started 12-24 h post-op, then × 14 days or until discharge DVT (proximal)
E-2
P-1 0
PE
E-0
P-0
Planes, 1988 [24] E = 124
H = 113
E - 40 mg SC starting 12 h (the day before surgery) pre-op, then qd × 14 days or until
discharge
DVT (all)
E-1 5
H-2 7
E-2
H-0
E-0
H-0
H - 5000 IU SC starting 2 h (on the day of surgery) pre-op, then tid × 14 days or until
discharge
DVT (proximal)
E-9
H-2 0
PE
E-2
H-3
Levine, 1991 [25] E = 333
H = 332
E - 30 mg SC bid, starting 12-24 h post-op, then bid × 14 days or until discharge DVT (all)
E-5 7
H-6 3
E-1 1
H-1 9
E-0
H-2
E-0
H-0
H - 7500 IU SC bid, starting 12-24 h post-op, then bid × 14 days or until discharge DVT (proximal)
E-1 6
H-1 8
PE
E-0
H-1
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Colwell, 1994 [26] E1 = 195
E2 = 205
H = 210
E1 - 30 mg SC q 12 h × 7 days E2 - 40 mg SC qdx 7 days H - 5000 IU SC q 8 h × 7 days DVT (all)
E1 - 9
E2 - 30
H-2 4
E1 - 8
E2 - 3
H-1 3
E1 - 7
E2 - 3
H-5
E1 - 1
E2 - 0
H-2
DVT (proximal)
E1 - 4
E2 - 8
H-1 0
PE
E-0
H-3
Avikainen, 1995
[27]
E=8 3
H=8 4
E - 40 mg SC qd, starting 12 h pre-op, then qd × 10 days DVT (all/proximal)
E-1
H-4
E-7
H-7
H - 5000 IU SC bid, starting 2 h pre-op and 12 h post-op, then bid × 10 days PE
E-0
H-1
Bergqvist,1996
[28]
E = 131
P = 131
E - 40 mg SC qd starting 12 h pre-opx 7-11 days then 40 mg SC qd post-op × 21 days DVT (all)
E-2 1
P-4 5
E-1
P-0
E-0
P-0
E P - 40 mg SC qd starting 12 h pre-op × 7-11 days then placebo qd post-op up to 21 days DVT (proximal)
E-8
P-2 8
PE
E-0
P-2
Planes, 1996 [29] E = 90
P=8 9
E - 40 mg SC qd × 21 days P - qd × 21 days DVT (all)
E-6
P-1 7
E-0
P-0
E-0
P-0
E-0
P-0
DVT (proximal)
E-5
P-7
PE
E-0
P-0
Rader, 1998 [30] E = 70
H=5 6
E - 5000 IU SC PM pre-op and AM and PM op day, then post-op enoxaprin 40 mg SC qd ×
13-21 days
DVT (all)
E-2
H-1
E-0
H-0
H - 5000 IU SC PM pre-op and AM and PM op day, then 5000 IU SC tid × 3 days, then 7500
IU tid on 4th day post-op × 13-21 days
PE E - 0 H - 0
Comp, 2001 [31] E = 224
P = 211
E - 30 mg SC bid, starting 12-24 h post-op and continuing 7-10 days; then enoxaparin 40
mg SC qd × 18-21 days
DVT (all)
E-1 8
P-4 9
E-0
P-0
E-3
P-2
P - enoxaparin 30 mg SC bid, starting 12-24 h post-op and continuing 7-10 days; then
placebo qd × 18-21 days
DVT (proximal)
E-6
P-2 7
PE
E-0
P-1
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Senaran, 2006
[32]
E=5 0
H=5 0
E - 40 mg SC qd, starting 12 h pre-op × 7-10 days until discharge DVT during
hospitalization (first 7-
10 days)
E-0
H-2
E-2
H-0
E-0
H-0
E-0
H-0
H - 5000 IU SC, starting q 8 h pre-op, then continued to 15,000 IU qd in 3 equal doses q 8
h × 7-10 days until discharge
DVT within 45 days
after discharge
E-2
H-0
* 45 day post discharge follow up PE
E-0
H-0
Fuji, 2008 [33] E1 = 104
E2 = 105
E3 = 107
P = 105
E1 - 20 mg SC qd, started 24-26 h post-op, then qd × 14 days DVT (all)
E1 - 21
E2 - 18
E3 - 27
P-3 6
E1 - 1
E2 - 3
E3 - 2
P-0
E2 - 20 mg SC bid, started 24-26 h post-op then qd × 14 days
E3 - 40 mg SC qd, started 24-26 h post-op, then qd × 14 days DVT (proximal)
E1 - 3
E2 - 3
E3 - 6
P-9
P - qd × 14 days
*Follow-up at 90 days after surgery PE
E1 - 0
E2 - 0
E3 - 0
P-0
Abbreviations: D = dalteparin, E = enoxaparin, P = placebo, H = unfractionated heparin, SC = subcutaneously, W = warfarin, IV = intravenously, THR = total hip replacement, HIT = heparin induced thrombocytopenia,
VTE = Venous thromboembolism, S = symptomatic, DVT = deep vein thrombosis, PE = pulmonary embolism.
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Common Control
There were a total of seven trials that compared enoxaparin
or dalteparin to UH. The trials provided a total of 7 treat-
ment arms suitable for meta analysis, five and two for enoxa-
parin and dalteparin respectively (Table 1). Regardless of the
LMWH, the meta analysis identified a trend where patients
randomized to a LMWH had a reduced risk for developing a
VTE following THR (RR = 0.83, p = 0.12) compared to UH
(Figure 3). When an analysis between drugs was undertaken,
the meta regression analysis suggested comparable efficacy
between enoxaparin and dalteparin, but a 22% relative
advantage was noted in favour of dalteparin which did not
reach statistical significance (Table 2).
A safety assessment was then undertaken using UH as
the control. Due to the lack of data, we were unable to
perform an indirect statistical comparison with respect
to major bleeding events and death. However, there was
no significant risk difference in the risk of HIT between
dalteparin and enoxaparin (Table 2). In summary, the
indirect statistical assessment of enoxaparin and dalte-
parin using meta regression analysis was unable to find
any statistically significant differences between drugs
with respect risk for VTEs, major bleeds, HIT and death
regardless of the control used (Table 2). Therefore,
these data support the comparative efficacy between
enoxaparin and dalteparin in THR patients.
Comparing Safety and Efficacy using the Method of
Bucher et al. (1997)
The indirect method developed by Bucher and colleagues
is one of the most cited approaches for performing indir-
ect comparisons of randomized trials [13,14]. It was
applied for the indirect assessment of enoxaparin vs. dal-
teparin with respect to VTE prevention and adverse
events such major bleeds, HIT and death in patients
undergoing THR surgery. As was previously suggested by
the meta regression analysis, there was no evidence to
suggest that one agent was better to another with respect
to VTE prevention following THR surgery (Table 3).
Similarly, there was no significant difference in the risk of
major bleeds, HIT and death between the drugs as indi-
cated by the 95%CIs for the RR which crossed the 1.0
threshold. Hence, these data imply that enoxaparin and
dalteparin have comparable safety and efficacy when
used to prevent VTEs in this high risk patient group.
                                                                                                        Favours LMWHs     Favours Placebo 
Figure 1 Meta analysis on the relative risk of VTEs in placebo-controlled trials evaluating enoxaparin or dalteparin in THR patients.
The pooled VTE relative risk was significantly different between pharmacotherapy (dalteparin or enoxaparin) vs. placebo; p < 0.001. Test for
heterogeneity: Chi
2 = 13.9, df = 10, p = 0.18, I
2 = 28.1%.
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The potential for publication bias was assessed. From
the placebo-controlled THR trials, asymmetry in the
funnel plot was detected (figure not shown) and the
p-value from the Egger test (p = 0.19) indicated the pos-
sibility of publication bias. In contrast, there was no evi-
dence to suggest publication bias with the UH-
controlled THR trials (the Egger test, p = 0.44).
Discussion
Dalteparin and enoxaparin have been available for DVT
prophylaxis since the early 1990s. Several large well
designed randomized trials demonstrated that these
agents were at least equivalent to UH and superior to
placebo for the prevention of VTEs follow major ortho-
pedic surgery [16,17]. However, there have been few
trials with sufficient sample size and statistical power to
assess the noninferiority between the two drugs. There-
fore, comparative outcomes in terms of safety and effi-
cacy between dalteparin and enoxaparin has not been
formally established [18]. Furthermore, the limited
patent life of these drugs make it unlikely that a large
noninferiority trial will be conducted to answer this
important question. Therefore, physicians have tended
to use “gut feeling” as opposed to formal evidence when
assessing the comparative efficacy between the drugs. In
the absence of direct comparative data, indirect statisti-
cal techniques are an appropriate alternative for provid-
ing the needed evidence [15]. In this study, two such
indirect methods were used to compare the products for
efficacy and safety as part of a larger meta analysis.
Our findings initially demonstrated that dalteparin and
enoxaparin are highly effective in preventing DVTs fol-
lowing THR surgery. THR patients randomized to the
LMWH arm of the trials were 50% less likely to develop
a VTE during the study period compared to placebo.
The drugs also had comparative effectiveness relative to
UH in preventing VTEs in the same patient population.
All of these benefits were achieved without an increase
in the occurrence of major bleeds, HIT and overall
mortality.
The evaluation was continued with a meta regression
analysis which was unable to detect statistically signifi-
cant differences between dalteparin and enoxaparin in
                                  Worse with Placebo    Worse with LMWHs 
Figure 2 Meta analysis on the relative risk for major bleeds in placebo-controlled trials evaluating enoxaparin or dalteparin in THR
patients. The pooled relative risk for major bleeds was not significantly different between pharmacotherapy (dalteparin or enoxaparin) vs.
placebo; p = 0.76. Test for heterogeneity: Chi
2 = 3.34, df = 7, p = 0.85, I
2 = 0.0%.
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Given the available data from prospective randomized
trials and the application of two indirect statistical tech-
niques, it is reasonable to conclude that dalteparin pro-
vides comparative safety and efficacy to enoxaparin
when used to prevent VTEs in patients undergoing
THR surgery. To our knowledge, this is the first study
to use indirect methods for comparing these two com-
monly used drugs.
The application of indirect statistical techniques in the
absence of large head to head randomized trials is a rea-
sonable approach to compare efficacy and safety between
dalteparin and enoxaparin [14,15]. However, there are
several limitations in this study that need to be acknowl-
edged. All meta-analyses are affected by the quality of the
studies analyzed. For that reason, we limited our review
to prospective randomized trials with sufficient sample
size. However given the nature of the intervention (i.e.
UH), not all of the trials were double blinded. Regardless
of the data source, our analysis was indirect and does not
replace a well designed non-inferiority trial comparing
the two drugs. Therefore, we must be aware of the poten-
tial biases associated with indirect comparisons. There
were only seven randomized trials suitable for meta ana-
lysis in studies that using UH as the control. It must be
acknowledged that this may have limited our statistical
power, so the risk of a type II error (i.e. false negative)
must be recognized as well as compromising our preci-
sion. The current analysis was not a true non-inferiority
study because a pre-specified “minimally clinically
important difference“ in efficacy between the two drugs
has not been established by regulatory authorities or the
academic community. Some of the trials provided more
that one two treatment arms for statistical analysis via
Table 2 Summary of meta regression analysis on the risk of VTE and adverse events in THR patients
Outcome LMWH (D or E) vs. Control SE P-Value Impact on Risk
VTE Risk in Placebo Trials Relative Risk
Both drugs vs. placebo 0.50 (0.40 - 0.61) <0.001 ↓by 50%
RR difference between drugs (E vs. D) 0.23 (i.e. 12%) 0.25 0.36 NS
Region (vs. North American)
European trial 0.33 0.49 0.50 NS
Global trial 0.20 0.58 0.73 NS
LMWH dosing
1 -0.09 0.53 0.87 NS
LMWH treatment duration
2 -0.21 0.31 0.51 NS
Year of publication 0.04 0.04 0.34 NS
Risk of Major Bleeds
Both drugs vs. placebo 1.19(0.39 - 3.55) 0.76 NS
Risk difference between Drugs (E vs. D) -0.94 1.25 0.45 NS
Risk of HIT
Both drugs vs. placebo 1.13 (0.36 - 3.53) 0.83 NS
RR difference between Drugs (E vs. D) -0.85 2.0 0.48 NS
Risk of Death
Both drugs vs. placebo 0.72 (0.22-2.34) 0.59 NS
RR difference between Drugs (E vs. D) 0.22 1.28 0.86 NS
VTE Risk in UH Trials
Both drugs vs. UH 0.83 (0.66-1.05) 0.12 NS
RR difference between drugs (E vs. D) -0.24 (i.e. - 22%) 0.61 0.66 NS
Risk of Major Bleeds
Both drugs vs. UH 0.70 (0.35-1.38) 0.30 NS
RR difference between Drugs (E vs. D) NA
Risk of HIT
Both drugs vs. UH 0.61 (0.21-1.77) 0.36 NS
RR difference between Drugs (E vs. D) 0.56 1.53 0.71 NS
Risk of Death
Both drugs vs. UH 0.59 (0.12-3.1) 0.53 NS
RR difference between Drugs (E vs. D) NA
Abbreviations: LMWH = low molecular weight heparin, D = dalteparin, E = enoxaparin, P = placebo, UH = unfractionated heparin, THR = total hip replacement,
VTE = venous thromboembolic events, HIT = heparin induced thrombocytopenia, NS = not significant, DVT = deep vein thrombosis, PE = pulmonary embolism,
NA = data not available for calculation.
1Pre vs. post surgical initiation.
2Short duration (i.e. < 15 days) vs. extended duration.
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assumption of regression modeling. Lastly, the failure to
find statistically significant differences in the clinical end-
points between the two drugs through indirect methods
does not confirm comparable efficacy. The only way to
definitively answer this question is through a non-
inferiority trial. However, it is a reasonable alternative in
the absence of such a clinical trial.
Conclusions
The findings of this meta analysis of prospective rando-
mized trials suggest that dalteparin and enoxaparin are
highly effective for VTE prophylaxis following THR and
surgery. Keeping in the mind the caveats associated with
cross trial statistical comparisons, our findings also sug-
gested comparable safety and efficacy between dalte-
parin and enoxaparin. Therefore, treatment decision
making should be based on patient preferences, ease of
administration and cost considerations.
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                                                                       Favours LMWHs     Favours UH 
Figure 3 Meta analysis on the relative risk VTEs in unfractionated heparin controlled trials evaluating enoxaparin or dalteparin in THR
patients. The pooled VTE relative risk was not significantly different between LMWHs (dalteparin or enoxaparin) vs. UH; p = 0.12. Test for
heterogeneity: Chi
2 = 7.42, df = 6, p = 0.28, I
2 = 19.1%.
Table 3 Summary of indirect statistical comparisons
between dalteparin and enoxaparin using the method of
Bucher et al., (1997)
Comparison RR: E vs. D (95%CI) P-Value
THR Patients: Placebo Trials
VTE 1.26 (0.85 - 1.88) 0.78
Major Bleeds 2.57 (0.22 - 29.8) 0.58
Thrombocytopenia 2.34 (0.22 - 24.4) 0.69
Death 0.80 (0.06 - 1.0) 0.90
THR Patients: UH Trials
VTE 1.30 (0.42 - 4.1) 0.49
Major Bleeds NA
Thrombocytopenia 0.57 (0.03 - 11.4) 0.94
Death NA (0.03 - 17.9) 0.94
Abbreviations: RR = relative risk, D = dalteparin, E = enoxaparin, P = placebo,
UH = unfractionated heparin, THR = total hip replacement, VTE = venous
thromboembolic events, NA = data not available for calculation.
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